Phase-out of CFCs in epinephrine inhalers
This article was originally published in The Gray Sheet
Executive Summary
FDA proposes elimination of "essential use" designation that continues to allow use of polluting chlorofluorocarbons in metered dose inhalers for epinephrine - available over-the-counter for mild asthma. The agency "has tentatively concluded that there are no substantial technical barriers to formulating epinephrine as a product that does not release CFCs," FDA explains in a Sept. 20 announcement. Inhalers with CFCs would be phased out by the end of 2010 under the proposed rule, on which FDA will seek public comment
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.